Day JW, Ottaway N, Patterson JT, et al
When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week
Patients with a history of reflux should be especially mindful when starting a GLP-1
These drugs help control blood sugar and may lead to weight loss
While their glucose-lowering effects have been well documented for years, recent clinical breakthroughs have shown that these medications can deliver transformative weight loss, often rivalling or even surpassing results from bariatric surgery for certain patients
These are not small labs running manual synthesis